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The World Health Organization (WHO) currently recommends pre-screening
for past infection prior to administration of the only licensed dengue vaccine,
CYD-TDV. Using a threshold modelling analysis, we identify settings where
this guidance prohibits positive net-benefits, and are thus unfavourable.
Generally, however, our model shows test-then-vaccinate strategies can
improve CYD-TDV economic viability: effective testing reduces unnecessary
vaccination costs while increasing health benefits. With sufficiently low testing
cost, those trends outweigh additional screening costs, expanding the range of
settingswith positive net-benefits. Thiswork highlights two aspects for further
analysis of test-then-vaccinate strategies.We found that starting routine testing
at younger ages could increase benefits; if real tests are shown to sufficiently
address safety concerns, themanufacturer, regulators andWHO should revisit
guidance restricting use to 9-years-and-older recipients. We also found that
repeat testing could improve return-on-investment (ROI), despite increasing
intervention costs. Thus, more detailed analyses should address questions on
repeat testing and testing periodicity, in addition to real test sensitivity and
specificity. Our results follow from a mathematical model relating ROI to
epidemiology, intervention strategy, and costs for testing, vaccination and
dengue infections.We applied thismodel to a range of strategies, costs and epi-
demiological settings pertinent toCYD-TDV.However, general trendsmaynot
apply locally, sowe provide our model and analyses as an R package available
via CRAN, denvax. To apply to their setting, decision-makers need only local
estimates of age-specific seroprevalence and costs for secondary infections.
1. Introduction
Global incidence of symptomatic dengue is estimated at 50–100 million cases
annually, with burden concentrated in low- and middle-income countries [1,2].
While many organizations advocate various dengue control measures, these
settings have limited resources and many competing options to improve quality
of life; thus, potential control efforts must be prioritized. One option, the only
currently licensed dengue vaccine, CYD-TDV (commercially: Dengvaxia), pre-
sents a complicated assessment: there is potential benefit, but also safety risks
and associated mitigation costs.
Dengue infections elicit complex immune responses, particularly in regions
where people typically experience multiple infections. There are four known
dengue serotypes; infection by one confers apparently lifelong immunity to it,
and temporary immunity to others.Disease threat varies substantially by infection
number: primary infections are generally asymptomatic, and when symptomatic
are rarely severe; secondary infections are more often symptomatic, and more
often severe; and post-secondary infections are almost always asymptomatic.
© 2019 The Authors. Published by the Royal Society under the terms of the Creative Commons Attribution
License http://creativecommons.org/licenses/by/4.0/, which permits unrestricted use, provided the original
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This pathogenicity pattern is caused by antibody-dependent
enhancement [3,4]. To avoid enhancement, vaccine develop-
ment has focused on products effective against all serotypes.
Though CYD-TDV initially appeared to achieve this goal
[5,6], subsequent work concluded that the vaccine acted more
like a silent natural dengue infection [7–11]: enhancing disease
risk in seronegative (i.e. no prior dengue infection) recipients
while being efficacious for previously infected recipients [12].
These disparate outcomes pose ethical challenges.
A multi-model comparison study estimated that using
CYD-TDV in high-burden settings would reduce both moder-
ate and severe cases overall [13]. These findings informed initial
recommendationsby theWorldHealthOrganization (WHO) to
consider CYD-TDV for settingswith high seroprevalence in the
target age for routine vaccination, with a minimum target age
of 9 years old to increase the likelihood of past infection [14].
Continuing observation in trial populations confirmed
increased risk of severe outcomes in seronegative recipients
[15]. The Strategic Advisory Group of Experts on Immuniza-
tion (SAGE) suggested avoiding this risk by verifying prior
infection with serological testing [16] and WHO revised
its recommendations accordingly [17,18]. Practically, the revised
guidance necessitates a point-of-care rapid diagnostic test
(RDT); as of July 2019, no such test exists, precluding
test-then-vaccinate strategies.
AtUS$78per vaccinated individual,CYD-TDVisamarginal
investment in many settings [13], so adding costs would see-
mingly decrease its attractiveness. But screening can plausibly
optimize use, limiting vaccination to the individuals likely to
benefit. Toprovide adecision tool for such investment,wedevel-
oped a model of the relationship between three pertinent costs:
secondary infections, vaccination and testing. Local decision-
makers can use this approach for their specific circumstances
to determine if CYD-TDV is worth further consideration. The
model has deliberately generous assumptions, providing a
simple way to reject CYD-TDV for a region, but additional
work, usingmore realistic assumptions, is required to determine
whether CYD-TDV is sufficiently beneficial.
Using this model, we found that test-then-vaccinate strat-
egies generally provide health benefits compared with both
non-vaccination and vaccination without testing, but not
necessarily outweighing the additional costs. We evaluate the
balance of benefits and costs using return-on-investment (here-
after ROI; net benefit per unit cost), which also enables
comparison against other development options.
We found that test-then-vaccinate strategies typically yield
their highestROIwhen testing startsyounger than the currently
recommended 9 years. We also found ROI improves with
periodic re-testing of initially seronegative individuals.
2. Methods
We derive ROIs using two limiting assumptions. We ignore
transmission, and thus indirect vaccination benefits, and assume
interventions work deterministically. Treating dengue incidence
like an environmental risk is justified in endemic settings, given
the predicted limited impact on transmission from CYD-TDV
[13]. Assuming that the intervention is deterministic provides
upper benefit limits. Because more realistic assumptions will
reduce benefits, local authorities may reject CYD-TDV (e.g. for
insufficient ROI) with this framework, but would need a more
detailed model (e.g. incorporating test sensitivity and specificity
based on real trials, incomplete vaccine efficacy in seropositive
recipients) to justify positive ROI estimates.
The electronic supplementary material provides derivations;
the R package, denvax, implements the analyses [19].
2.1. Dengue disease and CYD-TDV models
We represent dengue disease with three infection outcomes—pri-
mary like, secondary like and post-secondary like—each with
cost reflecting their respective disease risk and severity. Note that
these average costs include all outcomes, fromasymptomatic infec-
tions to death. We assume secondary infections have the highest
cost, and post-secondary infections have zero cost. We assume
CYD-TDV acts like a silent natural infection, preventing one of
these outcomes, and testing reveals an individual’s infection his-
tory. Figure 1 shows life trajectories under different interventions.
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Figure 1. Lifetime outcomes by intervention. Trajectories shown for no vaccination, vaccination without testing and vaccination with multiple testing. Each path
represents a possible life history, resulting in health outcome and intervention costs weighted by share of population following that path. For detailed branching
probabilities, see electronic supplementary material, figures S2–S4 and S7–S8. (Online version in colour.)
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2.2. Vaccination, testing and cost model
We calculate individual lifetime costs, using average primary and
secondary infection costs (F, S) weighted by relevant life history
probabilities denoted NPX{A} (probability of N out of X lifetime
infections by testing age A). Costs also include testing and, poten-
tially, vaccination (T, V) during the intervention window.
Strategies are defined by initial testing age and maximum allowed
tests (L) at a rate of one per year. Themodel denotes the seroconver-
sionprobabilitybetweenageA andA + 1 asC{A},whichdetermines
the average test count. We estimate these probabilities with the
exposure model described in the next section. We considered two
test mechanisms: binary, detecting only the presence of past infec-
tion, and ordinal, detecting the number of past infections. Because
the ordinal test also eliminates vaccination costs for people with
multiple past infections, it is always more effective (ignoring cost).
Though ordinal tests are theoretically better, we expect binary
tests are more realistic, and assumed them for our general results.
Using these assumptions, we derived equation (2.1). The left
side has intervention costs: weighted average number of tests
administered, 〈n(A, L)〉 (equation (2.2)), and probability of vacci-
nation, PyV{AþL1} (equation (2.3)), for a particular strategy. The
right side is the lifetime difference in health costs. For all inter-
ventions with testing, first infection cost, F, cancels. Therefore,
we can generalize across settings by expressing intervention
costs relative to secondary infection costs: ν =V/S and τ = T/S.
hn(A, L)ity  PyV{AþL1}n  (P2þ  0P2þ {AþL1}þ 2þP8),
(2:1)
hn(A, L)i ¼ 1þ 0P8{AþL1}(L1)
þ
XL2
i¼0
C{Aþ i}0P1þ {Aþ i}ðiþ 1Þ (2:2)
and PyV{AþL1} ¼ 1 0P8{AþL1}: (2:3)
ROI is the net benefits (difference in health outcome costs
minus the intervention cost) per intervention cost,
P2þ  2þP8  0P2{Aþ L 1}
hn(A, L)ity  PyV{AþL1}n
 1  0, (2:4)
for positive returns.
To identify circumstances where adding testing increases
intervention benefits, we compared vaccination with and with-
out testing, which produces a similar equation, but which
depends on F,
hn(A, L)it þ (1 PV {AþL1})n
 (0P1þ  0P2þ {AþL1}) 0P1þ FS : (2:5)
2.3. Dengue infection and intervention model
We model dengue exposure in annual increments: each year, an
individual is potentially exposed. We divide the population into
risk groups, low and high. Thus, the exposure model has three
parameters: pH, population fraction at high risk; and the annual
avoidance probability for low (sL) and high (sH) risk groups.
The probability of being seropositive at age A is thus
Pþ{A} ¼ rH(1 sAH)þ (1 rH)(1 sAL ): (2:6)
We use a maximum likelihood approach to fit this model to
age-seroprevalence data, then use the parameters to simulate
exposure histories. For each life-year, we uniformly select one of
the four serotypes to cause exposures, then probabilistically
expose individuals based on their risk. Exposure leads to infection,
unless the individualwas (i) previously infected by this serotype or
(ii) infected in the previous year. We estimate lifetime outcome
probabilities by aggregating many simulated individual histories.
3. Results
In these sections, we demonstrate the types of analyses avail-
able to the decision-makers using the models described
above. Because each region will differ, in costs, epidemiology
and decision criteria, we cannot present a singular recommen-
dation.We illustrate detailed application of the frameworkwith
two examples including particular epidemiology and costs, but
these are demonstrations, not conclusive results.
3.1. General trends
We applied our model across a range of epidemiological
settings and potential relative costs. Figure 2 shows test-then-
vaccinate strategies that start after age 4, testing annually
until a recipient is seropositive and thus vaccinated or reaches
a maximum age (up to 20 in these results). For each epidemio-
logical setting and relative cost, we report the lifetime value for
the optimal strategy (i.e. the pair of initial andmaximumtesting
ages that maximize ROI). We can view the same results from a
different angle to understand trends in initial testing age and
maximum number of tests. Figure 3 highlights the general
trend that testing earlier is better, but this effect depends on epi-
demiological setting and costs. Some regions have a minimum
numberof tests for positive ROI; others, amaximum.We found
trend reversions in several cases; while atypical, they highlight
the need for context-specific analyses.
3.2. Model implementation and practical demonstration
While the general results suggest trends, they also identify
the need for region-specific analyses. To that end, we
implemented the model in an R package, denvax, which
can be used with local epidemiological and economic data.
We demonstrate applying the approach with two practical
examples for Malaysia and Peru, using epidemiological data
from CYD14 [20] and a long-term study of Iquitos, Peru [21],
and crude economic assumptions from previous studies [13].
We use the serological data to fit the two-risk, constant-FOI
model, and then estimate the coefficients for equation (2.4).
For this example, we assume disease and intervention costs,
but decision-makers would estimate these from their regional
data.Given local policy, disease costmight bebasedon avariety
ofmeasures, such as hospital costs, lost productivity or willing-
ness topay.Vaccinationcost estimates couldbebasedonquoted
prices, and delivery costs derived from existing programmes
with similar deliverystrategies, e.g. humanpapillomavirus vac-
cine. Though costs are not yet available for an improved RDT,
decision-makers could use the model to understand the
maximum affordable test cost given other assumptions.
Herewe assume that vaccination (i.e. full dose regimen and
service delivery) costs US$78 per fully vaccinated child in both
locations [13].We assume testing costs ofUS$5per recipient per
year of testing (likewise full testing and service delivery).
Finally, we assume the regions differ by secondary infection
cost, using the South East Asian and Latin American societal
costs from [13], US$86 and US$223, respectively. Thus for
equation (2.4), the test and vaccine cost fractions are {τ,
ν} = {0.06, 0.91} for Malaysia and {0.02, 0.35} for Peru.
Since we are assuming costs, we focus on ROI for varying
initial and maximum testing ages in figure 4. The settings
produce very different surfaces, and highlight the importance
of initial testing age when evaluating strategies. Given the
demonstration data, no strategy produced a positive ROI in
royalsocietypublishing.org/journal/rsif
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Malaysia, even with the ordinal test, and more testing
only decreases ROI. Peru presents a different story: test-
then-vaccinate strategies are beneficial if started young
enough, and repeat testing improves ROI for all ages in the
range considered, even for initial ages where single testing
has a negative ROI.
4. Discussion
We demonstrated an approach that identifies CYD-TDV vac-
cination scenarios worthy of further investigation, and
implemented a framework for local authorities to assess
their potential return-on-investment using region-specific
epidemiology and costs. It is impossible to provide universal
answers to how or whether CYD-TDV should be used, but it
is possible to describe a limiting relationship among a small
set of factors and ascertain general trends.
We identified two such trends that should inform work on
test-then-vaccinate strategies. First, repeat testingmay improve
cost-effectiveness over single testing; for some settings, this
occurs even with relatively high testing costs. Second, we
found routine test-then-vaccinate programmes often provide
better ROI when targeting younger recipients, including
those below the currently recommended 9 years old.
Since our model uses several optimistic assumptions, it is
only appropriate for ruling out CYD-TDV in unfavourable
settings, not for conclusively supporting its use. Justifying
CYD-TDV requires more model realism. Future work
should refine vaccine performance, which we know to be
imperfect even in seropositive recipients and which has
uncertain durability. Likewise, even the gold-standard tests
for detecting prior dengue infection provide imperfect classi-
fication, particularly in the presence of other circulating
arboviruses. Should a point-of-care RDT be licensed, it is
unlikely to have better performance than the current gold
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standard [22]. Including these details will thus necessarily
lead to lower ROIs than those estimated by our model.
However, incorporating insights from our model may
help recover benefits. For example, we found annually repeat-
ing testing generally has superior performance, and under
our assumptions biennial testing would be even better. This
suggests repeat testing with lower frequency may be more
cost-effective in more realistic models as well. Similarly, the
substantial ROI improvement for younger intervention ages
suggests that the current age guidelines for vaccination
should be revisited if safety can be guaranteed by a highly
specific test. Despite current licensing, CYD-TDV trials
included younger participants and, after controlling for sero-
positivity, found safe and efficacious outcomes [15]; both
the original and re-issued WHO guidance indicate that the
9-year-old limit is to ensure sufficiently high seroprevalence
in the target population.
Accounting for these potential advantages properly will
require more detailed data. Repeat testingmay enable econom-
ies of scale (e.g. cheaper per unit tests), but will impose
additional costs (e.g. record-keeping and service logistics). A
modelwith repeat testswill also need to represent how individ-
ual test results are correlated. A lower routine intervention age
will also affect test performance and vaccine efficacy. These
concerns should be addressed in test development, so that
data are available to inform future modelling work.
Multiple dengue vaccine candidates are currently in trials
[23,24]. While they may prove durably tetravalent, given the
complexdengue immunologyandvaccinedevelopmenthistory,
there is a risk that thesenewvaccineswill alsohavequirks.CYD-
TDV, the only currently licensed vaccine, is flawed but reason-
ably understood and available now. We provide a clear tool to
determinewhere it is not useful, butwealso show that following
the WHO-recommended test-then-vaccinate strategy for CYD-
TDVcan improve cost-effectiveness inmanysettingswhile satis-
fying clinical safety and ethical requirements, if a low-cost,
suitable performance test can be developed. Whether that
improvement is sufficient towarrant deploying the intervention
will require additional work and detailed local analyses.
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